Stoke Therapeutics Stock Analysis

Stoke Stock Analysis Notes

About 96.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.27. Stoke Therapeutics had not issued any dividends in recent years. The entity had 1:9 split on the 6th of June 2019. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases in the United States. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Stoke Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. To find out more about Stoke Therapeutics contact the company at 781 430 8200 or learn more at https://www.stoketherapeutics.com.

Stoke Therapeutics Investment Alerts

Stoke Largest EPS Surprises

View All Earnings Estimates

Stoke Therapeutics Environmental, Social, and Governance (ESG) Scores

Stoke Stock Institutional Investors

Note, although Stoke Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Stoke Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.85 B.

Stoke Profitablity

The company has Profit Margin (PM) of 0.2 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (4.05) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $4.05.

Management Efficiency

Stoke Therapeutics has return on total asset (ROA) of 0.052 % which means that it generated a profit of $0.052 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1502 %, meaning that it created $0.1502 on every $100 dollars invested by stockholders. Stoke Therapeutics' management efficiency ratios could be used to measure how well Stoke Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.31. Return On Capital Employed is expected to rise to -0.48 this year. At this time, Stoke Therapeutics' Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 58.2 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 224.3 M.

Technical Drivers

As of the 10th of February, Stoke Therapeutics has the Semi Deviation of 3.54, coefficient of variation of 1048.33, and Risk Adjusted Performance of 0.0847. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Stoke Therapeutics, as well as the relationship between them.

Stoke Therapeutics Price Movement Analysis

Stoke Therapeutics Insider Trading Activities

Stoke Therapeutics Outstanding Bonds

Stoke Therapeutics Predictive Daily Indicators

Stoke Therapeutics Corporate Filings

Stoke Therapeutics Forecast Models

Stoke Therapeutics' time-series forecasting models are one of many Stoke Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Stoke Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stoke Therapeutics Bond Ratings

Stoke Therapeutics financial ratings play a critical role in determining how much Stoke Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Stoke Therapeutics' borrowing costs.

Stoke Therapeutics Debt to Cash Allocation

Stoke Therapeutics currently holds 2.32 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Stoke Therapeutics has a current ratio of 10.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Stoke Therapeutics' use of debt, we should always consider it together with its cash and equity.

Stoke Therapeutics Total Assets Over Time

Stoke Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Stoke Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Stoke Therapeutics Debt Ratio

0.93

It seems most of the Stoke Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Stoke Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Stoke Therapeutics, which in turn will lower the firm's financial flexibility.

Stoke Therapeutics Corporate Bonds Issued

Stoke Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Stoke Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Stoke shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Stoke Therapeutics. By using and applying Stoke Stock analysis, traders can create a robust methodology for identifying Stoke entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Stoke analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Stoke analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Stoke Therapeutics stock analysis indicators help investors evaluate how Stoke Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Stoke Therapeutics shares will generate the highest return on investment. By understating and applying Stoke Therapeutics stock analysis, traders can identify Stoke Therapeutics position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.

Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.